Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Combinatorial Chemistry & High Throughput Screening
|
December 8, 2004
Multiplexed RT- PCR for high throughput screening applications
Derrick Maley, Jay Mei, Hong Lu, et al.
Journal of Clinical Pharmacology
|
May 26, 2017
Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia
Yan Li, Francisco Ramírez-Valle, Yongjun Xue, et al.
Haematologica
|
December 18, 2012
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
Meletios A Dimopoulos, Michel Delforge, Roman Hájek, et al.
Leukemia & Lymphoma
|
October 23, 2013
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial
Meletios A Dimopoulos, Antonio Palumbo, Roman Hajek, et al.
Combinatorial Chemistry & High Throughput Screening
|
March 23, 2004
Gene expression analysis for high throughput screening applications
Albert Pinhasov, Jay Mei, Dhammika Amaratunga, et al.
BMC Cancer
|
January 30, 2016
Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program
Xin Du, Jie Jin, Zhen Cai, et al.
International Journal of Hematology
|
March 11, 2015
Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment
Dao-bin Zhou, Li Yu, Xin Du, et al.
Journal of Hematology & Oncology
|
June 21, 2013
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
Jian Hou, Xin Du, Jie Jin, et al.
Cancer Research
|
March 19, 2024
ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation
Hui Yuwen, Huajing Wang, Tengteng Li, et al.
Leukemia & Lymphoma
|
January 15, 2016
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial
Clemens M Wendtner, Michael Hallek, Graeme A M Fraser, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Combinatorial Chemistry & High Throughput Screening
|
December 8, 2004
Multiplexed RT- PCR for high throughput screening applications
Derrick Maley, Jay Mei, Hong Lu, et al.
Journal of Clinical Pharmacology
|
May 26, 2017
Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia
Yan Li, Francisco Ramírez-Valle, Yongjun Xue, et al.
Haematologica
|
December 18, 2012
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
Meletios A Dimopoulos, Michel Delforge, Roman Hájek, et al.
Leukemia & Lymphoma
|
October 23, 2013
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial
Meletios A Dimopoulos, Antonio Palumbo, Roman Hajek, et al.
Combinatorial Chemistry & High Throughput Screening
|
March 23, 2004
Gene expression analysis for high throughput screening applications
Albert Pinhasov, Jay Mei, Dhammika Amaratunga, et al.
BMC Cancer
|
January 30, 2016
Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program
Xin Du, Jie Jin, Zhen Cai, et al.
International Journal of Hematology
|
March 11, 2015
Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment
Dao-bin Zhou, Li Yu, Xin Du, et al.
Journal of Hematology & Oncology
|
June 21, 2013
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
Jian Hou, Xin Du, Jie Jin, et al.
Cancer Research
|
March 19, 2024
ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation
Hui Yuwen, Huajing Wang, Tengteng Li, et al.
Leukemia & Lymphoma
|
January 15, 2016
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial
Clemens M Wendtner, Michael Hallek, Graeme A M Fraser, et al.
Page
of 2